Association of elevated Cox-2 immunopositivity (score 2–3) with clinicopathological parameters
| Clinicopathological parameter . | Cox-2 staining (positive/total) . | Cox-2 positive (%) . | Pa (odds ratio) . |
|---|---|---|---|
| Age at diagnosis (yr) | |||
| <50 | 147/418 | 35.2 | NS;b 0.167 |
| ≥50 | 442/1158 | 38.2 | (0.88; 0.69–1.12) |
| Tumor size (cm) | |||
| ≤2 cm | 288/894 | 32.2 | <0.0001 |
| >2 cm | 276/601 | 45.9 | (0.56; 0.45–0.70) |
| Axillary node status | |||
| Negative | 331/983 | 33.7 | =0.0001 |
| Positive | 231/530 | 43.6 | (0.66; 0.53–0.82) |
| Histologic gradec | |||
| I | 47/183 | 25.7 | <0.0001 |
| II | 181/492 | 36.8 | |
| III | 148/284 | 52.1 | |
| Histologic type | |||
| Ductal | 461/1155 | 39.9 | =0.0017 |
| Lobular | 74/251 | 29.5 | |
| Special | 48/156 | 30.8 | |
| ER | |||
| Negative | 234/447 | 52.3 | <0.0001 |
| Positive | 330/988 | 33.4 | (0.46; 0.36–0.58) |
| PgR | |||
| Negative | 314/643 | 48.8 | <0.0001 |
| Positive | 249/786 | 31.7 | (0.49; 0.39–0.61) |
| Tumor proliferation | |||
| Ki-67 <20% | 277/840 | 33.0 | <0.0001 |
| Ki-67 ≥20% | 264/489 | 54.0 | (0.42; 0.33–0.53) |
| p53 expression | |||
| Negative/Low | 391/1070 | 36.5 | <0.0001 |
| High | 143/242 | 59.1 | (0.40; 0.30–0.54) |
| HER-2 oncogene amplification | |||
| Negative | 425/1157 | 36.7 | <0.0001 |
| Positive | 132/262 | 50.4 | (0.57; 0.43–0.76) |
| Clinicopathological parameter . | Cox-2 staining (positive/total) . | Cox-2 positive (%) . | Pa (odds ratio) . |
|---|---|---|---|
| Age at diagnosis (yr) | |||
| <50 | 147/418 | 35.2 | NS;b 0.167 |
| ≥50 | 442/1158 | 38.2 | (0.88; 0.69–1.12) |
| Tumor size (cm) | |||
| ≤2 cm | 288/894 | 32.2 | <0.0001 |
| >2 cm | 276/601 | 45.9 | (0.56; 0.45–0.70) |
| Axillary node status | |||
| Negative | 331/983 | 33.7 | =0.0001 |
| Positive | 231/530 | 43.6 | (0.66; 0.53–0.82) |
| Histologic gradec | |||
| I | 47/183 | 25.7 | <0.0001 |
| II | 181/492 | 36.8 | |
| III | 148/284 | 52.1 | |
| Histologic type | |||
| Ductal | 461/1155 | 39.9 | =0.0017 |
| Lobular | 74/251 | 29.5 | |
| Special | 48/156 | 30.8 | |
| ER | |||
| Negative | 234/447 | 52.3 | <0.0001 |
| Positive | 330/988 | 33.4 | (0.46; 0.36–0.58) |
| PgR | |||
| Negative | 314/643 | 48.8 | <0.0001 |
| Positive | 249/786 | 31.7 | (0.49; 0.39–0.61) |
| Tumor proliferation | |||
| Ki-67 <20% | 277/840 | 33.0 | <0.0001 |
| Ki-67 ≥20% | 264/489 | 54.0 | (0.42; 0.33–0.53) |
| p53 expression | |||
| Negative/Low | 391/1070 | 36.5 | <0.0001 |
| High | 143/242 | 59.1 | (0.40; 0.30–0.54) |
| HER-2 oncogene amplification | |||
| Negative | 425/1157 | 36.7 | <0.0001 |
| Positive | 132/262 | 50.4 | (0.57; 0.43–0.76) |